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Methods: DISCOVER comprises two similar 3-year prospective observational studies
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Results: Overall, 54.2% of patientsweremale (across region range [ARR]: 37.7–58.6%). At base-
line,mean age and time since diagnosis of type 2 diabetesmellituswere 57.2 (ARR: 53.1–61.9)
and 5.6 (ARR: 4.6–6.9) years, respectively. Median glycated haemoglobin (HbA1c) was
63.9 mmol/mol (8.0%; ARR: 7.6–8.3%). Microvascular and macrovascular complications were
reported in 18.9% (ARR: 14.5–23.5%) and 12.7% (ARR: 5.0–26.6%) of patients, respectively.
First-line treatments were mostly metformin monotherapy (55.6%; ARR: 42.5–83.6%) and
combinations ofmetforminwitha sulfonylurea (14.4%;ARR: 5.8–31.1%). Themost commonly
prescribed second-line therapies were combinations of metformin with a dipeptidyl
peptidase-4 inhibitor (23.5%; ARR: 2.2–29.6%) or a sulfonylurea (20.9%; ARR: 13.6–57.1%).
Conclusions: DISCOVERdemonstrates considerable global variation in the treatment of type 2
diabetes mellitus, and a need for more aggressive risk factor control.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
An estimated 425 million adults had diabetes worldwide in
2017, and this number is predicted to rise to 629 million by
2045 [1]. Type 2 diabetes mellitus accounts for approximately
90% of cases. This increase in the prevalence of type 2
diabetes mellitus will result in a large economic and social
burden, and is likely to occur predominantly in low- to
middle-income countries, where approximately three-
quarters of people with type 2 diabetes mellitus live [1].
Cross-sectional studies have clearly demonstrated that gly-
caemic control and management of comorbidities are subop-
timal in both high-income [2,3] and low- to medium-income
countries [4,5]. In many regions, however, longitudinal data
on glucose-lowering treatment patterns and associated out-
comes are scarce or non-existent.
Sustained glycaemic control, along with the management
of comorbidities such as hypertension and hyperlipidaemia,
remains a key component of the effective treatment of
patients with type 2 diabetes mellitus. Clinical guidelines rec-
ommend the use of metformin, in conjunction with lifestyle
changes, as the first-line glucose-lowering therapy [6–11].
However, when metformin monotherapy fails to control gly-
cated haemoglobin (HbA1c) levels, there is no consensus on
optimal subsequent treatments, and guidelines recommend
an individualized and patient-centred approach to drug selec-
tion based on patient characteristics including age, duration
of diabetes, presence of comorbidities and risk of adverse
events including hypoglycaemia and weight gain [8]. Beyond
glycaemic control, recent large cardiovascular outcome trials
[12–15] and a large multinational observational study [16]
have shown that some glucose-lowering therapies signifi-
cantly reduce the risk of cardiovascular complications in
patients with high cardiovascular risk, suggesting that treat-
ment patterns may have a significant effect on the develop-
ment of diabetes-related complications.
DISCOVER is a programme of observational research
involving 15,992 patients with type 2 diabetes mellitus mov-
ing from a first-line to a second-line glucose-lowering therapy
in 38 countries across six continents. First- and second-line
treatments could be mono or combination therapies, and
patients who were prescribed an injectable agent as first-
line therapy were excluded. The aim of the study is to provide
a global picture of type 2 diabetes mellitus treatment and clin-
ical outcomes, including in many rarely studied low- and
middle-income countries. The use of standardized data col-
lection methodology allows comparison between regions
and countries. Patients initiating second-line therapy were
chosen as the focus of the study because of the diversity of
treatment options recommended at this stage of disease pro-
gression. The aim of the present analysis was to describe the
baseline characteristics and treatment of patients enrolled in
the study, and to compare these characteristics between
regions. The sampling methodology and diversity of clinical
sites from which patients have been recruited is also
described.
2. Subjects, materials and methods
The design and methodology of the DISCOVER study pro-
gramme have been reported in detail elsewhere [17,18] and
are briefly summarized below.
2.1. Study design
The DISCOVER study programme comprises two similar, 3-
year, prospective, observational (non-interventional) studies
conducted simultaneously in 38 countries: DISCOVER
(NCT02322762) in 37 countries (Algeria, Argentina, Australia,
Austria, Bahrain, Brazil, Canada, China, Colombia, Costa Rica,
Czech Republic, Denmark, Egypt, France, India, Indonesia,
Italy, Jordan, Kuwait, Lebanon, Malaysia, Mexico, the Nether-
lands, Norway, Oman, Panama, Poland, Russia, Saudi Arabia,
South Africa, South Korea, Spain, Sweden, Taiwan, Tunisia,
Turkey and the United Arab Emirates), and J-DISCOVER
(NCT02226822) in Japan. The study protocol was approved
by the appropriate clinical research ethics committees in each
country, and the relevant institutional review boards at each
site. The protocol complies with the Declaration of Helsinki,
the International Conference on Harmonisation of Good Clin-
ical Practice and the local regulations for clinical research.
2.2. Site and investigator selection
The characteristics of physicians and practices involved in
the management of patients with type 2 diabetes mellitus
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in each country were explored before starting the study, in
order to recruit as representative as possible a selection of
physicians and patients. Information was collated from
peer-reviewed articles, reports published by international
organizations such as the World Health Organization, and
from local diabetes experts who acted as coordinating inves-
tigators in each country. Healthcare system characteristics
considered included the proportions of different types of
health care provider (primary care physicians, diabetolo-
gists, endocrinologists, cardiologists and other specialists)
and practices (primary care centres, specialized diabetes
centres and different types of hospitals) treating patients
with type 2 diabetes mellitus in each country, as well as
location (urban vs. rural and geographical distribution
within a country) and funding source (public, private and
mixed). A list of candidate sites that would match these
characteristics as closely as possible was then established
for each country, and all of these sites were invited to par-
ticipate in the study. Among the invited sites, approximately
one-third were subsequently able to take part and recruited
patients into the study.
2.3. Patient recruitment
Inclusion and exclusion criteria were kept to a minimum to
reflect routine clinical practice (Supplementary Table 1).
Patients with type 2 diabetes mellitus initiating a second-
line glucose-lowering treatment (add-on or switching) after
first-line oral treatment with a monotherapy, dual therapy
or triple therapy were invited by their physician to participate
in the study. Patients using an injectable agent (ie, insulin or a
glucagon-like peptide-1 [GLP-1] receptor agonist) as first-line
therapy were excluded from the study, as they are likely to
represent a group of patients with a more severe disease pro-
file who should be studied separately. The study protocol sta-
ted that investigating physicians should invite consecutive
eligible patients to take part in the study. All participating
patients provided signed informed consent.
2.4. Data collection
Data at baseline (initiation of second-line therapy) were col-
lected using a standardized electronic case report form, and
were transferred to a central database via a web-based data
capture system. Some data were extracted from existing elec-
tronic medical records and health registries in Canada, Den-
mark, France, Norway and Sweden; an abbreviated
electronic case report form was used in these countries. Vari-
ables collected at baseline included: investigator characteris-
tics; patient socio-demographics (including information on
education level, working status and health insurance cover-
age); clinical data including laboratory test results; first-line
glucose-lowering therapy (treatments received by patients
before study baseline); second-line glucose-lowering therapy
(treatments prescribed at study baseline); reason(s) for the
change in glucose-lowering therapy; HbA1c target set by the
physician at the time of therapy change; comorbidities
(including existing diabetes-related microvascular and
macrovascular complications); and co-medications. In line
with the observational nature of the study, clinical variables
such as HbA1c and fasting plasma glucose (FPG) were mea-
sured in accordance with routine clinical practice at each site.
Diagnosis and classification of complications relied on the
judgement of investigators and there was no external inde-
pendent adjudication of events.
2.5. Regional classification
Descriptive baseline data are reported for the overall DIS-
COVER population and by regions, based on the World Health
Organization regional classification (Supplementary Fig. 1):
Africa (Algeria and South Africa); the Americas (Argentina,
Brazil, Canada, Colombia, Costa Rica, Mexico and Panama);
South-East Asia (India and Indonesia); Europe (Austria, Czech
Republic, Denmark, France, Italy, the Netherlands, Norway,
Poland, Russia, Spain, Sweden and Turkey); the Eastern
Mediterranean (Bahrain, Egypt, Jordan, Kuwait, Lebanon,
Oman, Saudi Arabia, Tunisia and United Arab Emirates); and
the Western Pacific (Australia, China, Japan, Malaysia, South
Korea and Taiwan).
2.6. Statistical analysis
Categorical data are presented as numbers and percentages.
Mean (standard deviation [SD]) values, median (interquartile
range [IQR]) values and across-region ranges (ARRs) are
reported, when appropriate. Statistical analyses were carried
out using the SAS statistical software system (SAS Institute,
Inc., Cary, NC, USA).
3. Results
3.1. Site characteristics
A total of 778 sites in 38 countries are participating in the
study programme (Table 1). Approximately half of all sites
are primary care centres (50.5%; ARR: 15.6–67.7%) and the
majority are located in urban areas (72.5%; ARR: 51.6–
100.0%). In Europe and the Western Pacific region, primary
care centres are most common (67.7% and 51.3%, respec-
tively); hospitals and specialized diabetes centres are most
common in other regions (37.3–60.0%). Overall, the propor-
tions of sites publicly and privately funded are 37.1% and
61.8%, respectively, with variability between regions; 1.0% of
sites are both privately and publicly funded. Overall, investi-
gators are mainly endocrinologists or diabetologists (45.7%),
primary care physicians (33.7%) or internists (14.8%). How-
ever, the distribution of specialities also varies across regions.
Primary care physicians are more common in Africa (50.0%)
and Europe (71.8%) than in other regions, where investigators
are predominantly specialists (endocrinologists, diabetolo-
gists or internists; 78.1–96.1%).
Where possible, we compared the characteristics of
included sites and investigators to the information collated
before the start of the study for each country. The results of
this comparison are shown in Supplementary Fig. 2. Overall,
some over-representation of sites from urban locations and
specialist care centres was identified.
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Table 1 – Characteristics of sites participating in the DISCOVER study.
Total Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific
(N = 778) (n = 32) (n = 70) (n = 41) (n = 308) (n = 102) (n = 225)
Type of centre
Primary care centre 387 (50.5) 5 (15.6) 19 (27.5) 9 (22.5) 203 (67.7) 36 (35.3) 115 (51.3)
General/community hospital 91 (11.9) 1 (3.1) 2 (2.9) 8 (20.0) 22 (7.3) 13 (12.7) 45 (20.1)
University/teaching hospital 127 (16.6) 9 (28.1) 14 (20.3) 4 (10.0) 33 (11.0) 16 (15.7) 51 (22.8)
Specialized diabetes centre 64 (8.3) 5 (15.6) 19 (27.5) 12 (30.0) 15 (5.0) 9 (8.8) 4 (1.8)
Other type of centre 98 (12.8) 12 (37.5) 15 (21.7) 7 (17.5) 27 (9.0) 28 (27.5) 9 (4.0)
Missing 11 0 1 1 8 0 1
Location of centre
Urban 555 (72.5) 29 (90.6) 68 (100.0) 33 (82.5) 210 (69.8) 100 (98.0) 115 (51.6)
Rural 211 (27.5) 3 (9.4) 0 (0.0) 7 (17.5) 91 (30.2) 2 (2.0) 108 (48.4)
Missing 12 0 2 1 7 0 2
Centre funding
Public/governmental 283 (37.1) 12 (38.7) 11 (16.2) 8 (20.5) 161 (53.7) 27 (26.7) 64 (28.7)
Private 471 (61.8) 19 (61.3) 56 (82.4) 31 (79.5) 138 (46.0) 71 (70.3) 156 (70.0)
Mixed 8 (1.0) 0 (0.0) 1 (1.5) 0 (0.0) 1 (0.3) 3 (3.0) 3 (1.3)
Missing 16 1 2 2 8 1 2
Speciality of main investigator
PCP/family doctor 259 (33.7) 16 (50.0) 2 (2.9) 4 (10.0) 216 (71.8) 3 (2.9) 18 (8.0)
Endocrinology/diabetology 351 (45.7) 6 (18.8) 50 (72.5) 30 (75.0) 62 (20.6) 49 (48.0) 154 (68.8)
Internal medicine 114 (14.8) 8 (25.0) 9 (13.0) 6 (15.0) 21 (7.0) 49 (48.0) 21 (9.4)
Cardiology 29 (3.8) 1 (3.1) 5 (7.2) 0 (0.0) 0 (0.0) 1 (1.0) 22 (9.8)
Nephrology 3 (0.4) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9)
Geriatrics 1 (0.1) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other speciality 11 (1.4) 1 (3.1) 1 (1.4) 0 (0.0) 2 (0.7) 0 (0.0) 7 (3.1)
Missing 10 0 1 1 7 0 1
Main type of patient referral
Patient self-referral 460 (65.0) 23 (71.9) 32 (46.4) 21 (53.8) 176 (72.4) 35 (34.3) 173 (77.6)
Primary care referral 237 (33.5) 8 (25.0) 34 (49.3) 17 (43.6) 66 (27.2) 64 (62.7) 48 (21.5)
Secondary care referral 11 (1.6) 1 (3.1) 3 (4.3) 1 (2.6) 1 (0.4) 3 (2.9) 2 (0.9)
Missing 70 0 1 2 65 0 2
Estimated number of patients with type 2 diabetes mellitus per site and per month
<10 70 (9.2) 1 (3.2) 4 (5.8) 0 (0.0) 65 (22.2) 0 (0.0) 0 (0.0)
10–20 90 (11.9) 3 (9.7) 9 (13.0) 3 (7.5) 67 (22.9) 0 (0.0) 8 (3.6)
21–50 149 (19.6) 13 (41.9) 16 (23.2) 10 (25.0) 66 (22.5) 22 (21.6) 22 (9.8)
>50 450 (59.3) 14 (45.2) 40 (58.0) 27 (67.5) 95 (32.4) 80 (78.4) 194 (86.6)
Missing 19 1 1 1 15 0 1
PCP, primary care practitioner.
Data are reported as n (%), unless otherwise stated. Percentages calculated for all sites/investigators with data available; missing data are excluded.
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3.2. Patient socio-demographics
A total of 15,992 patients were enrolled in the study pro-
gramme (Supplementary Fig. 1; Table 2). Participants were
mostly Asian (49.7%) or Caucasian (25.6%), and 54.2% (ARR:
37.7–58.6%) were male. At the time of initiation of second-
line therapy, patients’ mean age was 57.2 years (SD:
12.0 years) with the highest mean age in Europe (61.9 years)
and the lowest in South-East Asia (53.1 years). A total of
52.3% (ARR: 42.4–63.1%) of patients were aged 41–60 years.
Overall, 48.9% of patients were employed or self-employed
(ARR: 39.4–55.5%), 28.0% were unemployed (ARR: 15.8–
41.8%), and 22.2% were retired (ARR: 9.9–43.0%). The highest
rates of unemployment were recorded in Africa (41.8%) and
South-East Asia (41.4%), and the lowest in Europe (15.8%).
Overall, 21.3% of patients did not have health insurance; this
proportion varied greatly across regions from 4.0% in Europe
to 67.8% in South-East Asia; overall, 62.5% of patients were
covered by public health insurance (ARR: 11.7–91.3%). >80%
of patients had received secondary or higher education
(ARR: 68.1–88.9%). Most participants stated that they were
lifetime non-smokers (69.4%; ARR: 56.1–91.7%) and lifetime
alcohol abstainers (65.8%; ARR: 44.9–92.6%).
3.3. Patient baseline clinical variables
Clinical variables at baseline are reported in Table 3. Themed-
ian time from diagnosis of type 2 diabetes mellitus to initia-
tion of second-line therapy was 4.1 years (IQR: 1.9–7.9 years;
mean [SD]: 5.6 [5.3]), and was lowest in South-East Asia and
Western Pacific region (3.4 years) and highest in Africa
(5.7 years). There was a high level of variability in median
time from diagnosis of type 2 diabetes mellitus between
countries (Supplementary Table 2). HbA1c and/or FPG levels
were the main measures of glycaemic control at the time of
initiation of second-line therapy and were reported for
79.9% (ARR: 57.5–93.7%) and 69.9% (ARR: 36.2–84.5%) of
patients, respectively; 11.1% (ARR: 1.7–30.7%) of patients had
an FPG measurement but no HbA1c measurement (data not
shown). In addition, post-prandial glucose (PPG) and random
glucose levels were reported in 31.4% and 17.8% of patients,
respectively. A total of 7.1% of patients did not have any mea-
sure of blood glucose levels reported, ranging from 2.7% in the
Eastern Mediterranean region to 34.7% in Africa (data not
shown). The median HbA1c level was 63.9 mmol/mol (8.0%)
(IQR: 55.2–76.0 mmol/mol [7.2–9.1%]) and was similar across
all regions (ARR: 59.6–67.2 mmol/mol [7.6–8.3%]) but varied
between countries (Supplementary Table 2). The overall pro-
portions of patients with HbA1c levels  7.0%, 7.0 to  8.0%,
8.0 to  9.0%, > 9.0% or more were 17.6%, 31.6%, 23.3% and
27.5%, respectively. The median FPG level was 8.8 mmol/l
(IQR: 7.3–10.9 mmol/l; ARR: 8.2–9.4 mmol/l).
The mean body mass index was 29.1 kg/m2 (SD: 5.9 kg/m2)
with the lowest values found in the Western Pacific region
(26.1 kg/m2) and the highest in Europe (31.9 kg/m2). Hyperten-
sion and hyperlipidaemia were recorded as comorbid condi-
tions by the investigators for 51.5% and 45.6% of patients,
respectively. Systolic blood pressure (SBP) and low-density
lipoprotein cholesterol (LDL-C) levels were reported for
95.4% and 54.8% of patients, respectively. Among these
patients, 67.7% had an SBP lower than 140 mmHg, and
43.4% had an LDL-C level lower than 100 mg/dl.
Microvascular complications (history of chronic kidney
disease, retinopathy, retinal laser photocoagulation, auto-
nomic neuropathy, peripheral neuropathy and erectile dys-
function), and macrovascular complications (history of
coronary artery disease, heart failure, angina, myocardial
infarction, percutaneous coronary intervention, coronary
artery bypass grafting, stroke, transient ischaemic attack, car-
otid artery stent, carotid endarterectomy, peripheral artery
disease, diabetic foot, amputation and defibrillator use) were
present in 18.9% (ARR: 14.5–23.5%) and 12.7% (ARR: 4.0–
26.6%) of patients, respectively.
3.4. First- and second-line therapies
First- and second-line therapies are described in Table 4. The
most prescribed first-line therapies were metformin
monotherapy (55.6%; ARR: 42.5–83.6%) and combinations of
metformin and a sulfonylurea (14.4%; ARR: 5.8–31.1%). The
proportion of patients who received combinations of met-
formin and a sulfonylurea as first-line therapies was particu-
larly high in South-East Asia and the Eastern Mediterranean
region (31.1% and 23.9%, respectively).
Overall, the most prescribed second-line therapies were
combinations of metformin and a dipeptidyl peptidase-4
(DPP–4) inhibitor (23.5%) and combinations of metformin
and a sulfonylurea (20.9%). Combinations of metformin and
a sulfonylurea were the most commonly prescribed second-
line therapies in Africa (57.1%) and South-East Asia (24.8%),
and combinations of metformin and a DPP-4 inhibitor were
the most commonly prescribed second-line therapies in the
Eastern Mediterranean region (29.6%), the Americas (29.2%),
Europe (27.5%) and the Western Pacific region (24.8%).
Monotherapies accounted for 12.8% of second-line treat-
ments, but this proportion varied across regions (ARR: 4.9–
15.8%). The overall prescription rate of insulin (on its own or
as part of a combination) was 7.8% (ARR: 4.7–10.7%). Of the
1237 patients who received insulin, 957 (77.4%) had an HbA1c
measurement; mean HbA1c was 9.9% (SD: 2.1%) (data not
shown).
The main reason for initiating a second-line therapy
reported by investigators was lack of efficacy of first-line ther-
apy (88.9%) (Fig. 1a), and the main reasons for choosing
second-line treatments were efficacy (61.4%), tolerability
(22.3%), low risk of weight gain (17.8%) and low risk of hypo-
glycaemic events (17.0%) (Fig. 1b). Lack of efficacy was also
the main reason reported for switching between monothera-
pies (data not shown).
4. Discussion
DISCOVER is a unique, global research programme that
assesses the characteristics, treatment and outcomes of
patients with type 2 diabetes mellitus after initiating
second-line glucose-lowering therapy. DISCOVER includes
778 clinical sites representing primary and secondary care,
rural and urban locations, and different funding sources.
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Table 2 – Socio-demographic characteristics of patients participating in the DISCOVER study.
Total Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific
(N = 15,992) (n = 812) (n = 2002) (n = 3360) (n = 3479) (n = 2182) (n = 4157)
Sex
Male 8664 (54.2) 306 (37.7) 963 (48.1) 1852 (55.1) 1856 (53.4) 1278 (58.6) 2409 (58.0)
Missing 4 0 0 0 4 0 0
Self-reported ethnicity
Caucasian 3917 (25.6) 105 (12.9) 480 (29.4) 1 (0.0) 3020 (94.8) 165 (7.6) 146 (3.5)
Black 310 (2.0) 235 (29.0) 61 (3.7) 0 (0.0) 13 (0.4) 0 (0.0) 1 (0.0)
Mixed 213 (1.4) 91 (11.2) 115 (7.0) 0 (0.0) 4 (0.1) 0 (0.0) 3 (0.1)
Asian 7610 (49.7) 177 (21.8) 9 (0.6) 3339 (99.5) 20 (0.6) 72 (3.3) 3993 (96.1)
Hispanic 942 (6.2) 1 (0.1) 928 (56.8) 0 (0.0) 11 (0.3) 0 (0.0) 2 (0.0)
Arabic 2151 (14.0) 200 (24.7) 4 (0.2) 2 (0.1) 12 (0.4) 1933 (88.9) 0 (0.0)
Other 174 (1.1) 2 (0.2) 36 (2.2) 15 (0.4) 104 (3.3) 5 (0.2) 12 (0.3)
Missing 675 1 369 3 295 7 0
Age, years
Mean (SD) 57.2 (12.0) 54.9 (11.2) 58.3 (11.8) 53.1 (11.3) 61.9 (10.9) 53.8 (10.8) 58.5 (12.6)
Median (IQR) 58.0 (48.3–65.7) 54.9 (48.0–63.0) 58.3 (50.5–66.3) 53.0 (43.0–63.0) 62.2 (54.3–69.4) 53.9 (46.7–61.0) 58.1 (49.8–67.4)
18–30 228 (1.4) 16 (2.0) 23 (1.1) 75 (2.2) 13 (0.4) 34 (1.6) 67 (1.6)
31–40 1192 (7.5) 69 (8.5) 117 (5.8) 391 (11.6) 99 (2.8) 224 (10.3) 292 (7.0)
41–50 3340 (20.9) 198 (24.4) 386 (19.3) 934 (27.8) 442 (12.7) 588 (26.9) 792 (19.1)
51–60 5028 (31.4) 290 (35.7) 653 (32.6) 1059 (31.5) 1034 (29.7) 789 (36.2) 1203 (28.9)
61–70 4126 (25.8) 175 (21.6) 526 (26.3) 715 (21.3) 1192 (34.3) 418 (19.2) 1100 (26.5)
71–80 1730 (10.8) 61 (7.5) 239 (11.9) 162 (4.8) 577 (16.6) 122 (5.6) 569 (13.7)
>80 348 (2.2) 3 (0.4) 58 (2.9) 24 (0.7) 122 (3.5) 7 (0.3) 134 (3.2)
Missing 0 0 0 0 0 0 0
Education level
No formal education 471 (3.2) 57 (7.3) 50 (3.2) 26 (0.8) 78 (2.5) 158 (7.7) 102 (2.7)
Primary (1–6 years) 2295 (15.8) 183 (23.3) 442 (28.7) 343 (10.4) 588 (19.1) 360 (17.6) 379 (10.0)
Secondary (7–13 years) 7190 (49.4) 420 (53.5) 587 (38.1) 1431 (43.2) 1781 (58.0) 767 (37.5) 2204 (58.0)
Higher education (>13 years) 4599 (31.6) 125 (15.9) 463 (30.0) 1514 (45.7) 626 (20.4) 759 (37.1) 1112 (29.3)
Missing 1437 27 460 46 406 138 360
Main working status
Employed 5465 (36.3) 262 (32.6) 473 (29.9) 877 (26.2) 1096 (34.1) 954 (45.5) 1803 (44.9)
Self-employed 1893 (12.6) 59 (7.3) 343 (21.7) 755 (22.5) 171 (5.3) 209 (10.0) 356 (8.9)
Disabled 82 (0.5) 6 (0.7) 6 (0.4) 0 (0.0) 59 (1.8) 2 (0.1) 9 (0.2)
Not working 4216 (28.0) 336 (41.8) 428 (27.1) 1388 (41.4) 507 (15.8) 684 (32.6) 873 (21.7)
Retired 3337 (22.2) 140 (17.4) 330 (20.9) 332 (9.9) 1381 (43.0) 247 (11.8) 907 (22.6)
Other 67 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 67 (1.7)
Missing 932 9 422 8 265 86 142
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Together with a broad spectrum of investigators (including
primary care practitioners, diabetologists, endocrinologists
and other specialists), the diversity of sites provides a com-
prehensive picture of the management of patients with type
2 diabetes mellitus in different clinical settings around the
world. In addition, the observational design, minimal inclu-
sion/exclusion criteria and global reach of DISCOVER ensure
that adults of all ages with different backgrounds, ethnicities
and socio-economic status are included.
Although clinical guidelines recommend monitoring
HbA1c to support treatment decisions, approximately one in
five patients did not have an HbA1c measurement recorded
when initiating second-line treatment, suggesting that HbA1c
is not routinely measured in some clinical settings and geo-
graphic regions. This suboptimal HbA1c reporting may be
partly explained by the fact that HbA1c measurement is not
affordable for some patients in many low- to middle-income
countries [19]. Our results suggest that, in such situations,
other measures of glycaemia such as PPG, FPG and self-
monitoring of blood glucose may have been used by some
physicians as alternatives to monitor glucose levels and to
support treatment decisions in routine clinical practice. How-
ever, 7.1% of patients had no recorded measure of blood glu-
cose levels, a higher proportion than would be expected
since all patients were changing treatment at the time of their
inclusion in the study.
As expected in a population of patients who were escalat-
ing from first- to second-line therapy, mean HbA1c levels were
above the target of 7.0% recommended by guidelines [8,10].
Mean HbA1c levels were largely similar across all regions
and were consistently high. Overall, >50% of patients for
whom HbA1c levels were reported had a measurement higher
than 8.0%, and approximately 30% had ameasurement higher
than 9.0%. This suggests suboptimal glycaemic control and
delayed treatment intensification in a large proportion of
patients, increasing their risk of microvascular andmacrovas-
cular complications [20,21]. The prevalence of vascular com-
plications and associated risk factors (hypertension and
hyperlipidaemia) also highlighted an opportunity to improve
the early management of patients with type 2 diabetes
mellitus.
The most common first-line therapy was metformin
monotherapy in all regions. However, overall only 55.6% of
all patients received metformin monotherapy at first-line, a
lower proportion than has been reported in some recent ret-
rospective observational studies conducted in Western coun-
tries [22–25]. In these studies, 65–91% of patients newly
diagnosed with type 2 diabetes mellitus received metformin
monotherapy as first-line treatment. This difference may be
explained, at least in part, by lower metformin monotherapy
usage in South-East Asia, the Eastern Mediterranean and the
Western Pacific, where less than 50% of patients were pre-
scribed metformin monotherapy at first line. The proportions
of patients receiving metformin monotherapy as first-line
treatment in Africa, the Americas and Europe were 83.6%,
77.1% and 67.1%, respectively; similar to the previous reports
[22–25].
Overall and in Africa, South-East Asia, Europe and the
Eastern Mediterranean region, the second most commonly
prescribed first-line treatment consisted of a combination of
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Table 3 – Baseline clinical characteristics of patients participating in the DISCOVER study.
Total
(N = 15,992)
Africa
(n = 812)
Americas
(n = 2002)
South-East Asia
(n = 3360)
Europe
(n = 3479)
Eastern
Mediterranean
(n = 2182)
Western Pacific
(n = 4157)
Time from diagnosis to initiation of second-line therapy, years
Mean (SD) 5.6 (5.3) 6.9 (5.7) 6.2 (6.3) 4.6 (4.1) 6.6 (5.4) 5.8 (5.3) 5.1 (5.4)
Median (IQR) 4.1 (1.9–7.9) 5.7 (2.9–9.3) 4.4 (1.9–8.7) 3.4 (2.0–6.1) 5.4 (2.7–9.1) 4.2 (2.1–8.0) 3.4 (1.0–7.6)
Missing 397 0 62 1 154 2 176
HbA1c, mmol/mol
Mean (SD) 67.7 (18.6) 70.3 (20.2) 69.3 (20.6) 70.8 (18.5) 65.4 (17.1) 71.1 (17.2) 64.9 (18.6)
Median (IQR) 63.9 (55.2–76.0) 63.9 (57.2–79.2) 63.9 (55.2–79.2) 67.2 (58.5–81.4) 62.0 (55.0–72.0) 67.2 (59.6–79.2) 59.6 (53.0–71.6)
Missing 3208 345 471 1309 476 137 470
HbA1c, %
Mean (SD) 8.3 (1.7) 8.6 (1.9) 8.5 (1.9) 8.6 (1.7) 8.1 (1.6) 8.7 (1.6) 8.1 (1.7)
Median (IQR) 8.0 (7.2–9.1) 8.0 (7.4–9.4) 8.0 (7.2–9.4) 8.3 (7.5–9.6) 7.8 (7.2–8.7) 8.3 (7.6–9.4) 7.6 (7.0–8.7)
<7.0 2249 (17.6) 57 (12.2) 262 (17.1) 274 (13.4) 561 (18.7) 196 (9.6) 899 (24.4)
7.0 to <8.0 4039 (31.6) 162 (34.7) 460 (30.0) 530 (25.8) 1056 (35.2) 507 (24.8) 1324 (35.9)
8.0 to <9.0 2983 (23.3) 94 (20.1) 336 (21.9) 515 (25.1) 732 (24.4) 648 (31.7) 658 (17.8)
9.0 3513 (27.5) 154 (33.0) 473 (30.9) 732 (35.7) 654 (21.8) 694 (33.9) 806 (21.9)
Missing 3208 345 471 1309 476 137 470
FPG, mmol/l
Mean (SD) 9.5 (3.1) 9.7 (3.5) 9.8 (3.4) 9.3 (3.0) 9.3 (3.0) 10.1 (3.3) 9.0 (2.9)
Median (IQR) 8.8 (7.3–10.9) 8.7 (7.3–11.3) 8.8 (7.4–11.3) 8.8 (7.1–10.9) 8.6 (7.4–10.5) 9.4 (7.8–11.7) 8.2 (7.0–10.3)
Missing 4811 518 611 625 890 338 1829
PPG, mmol/l
Mean (SD) 12.6 (4.3) 12.4 (4.6) 11.2 (4.2) 13.1 (4.2) 11.5 (3.8) 14.0 (3.9) 11.8 (4.4)
Median (IQR) 12.0 (9.6–14.9) 11.3 (9.5–13.4) 10.7 (8.2–13.6) 12.5 (10.3–15.5) 10.8 (9.0–13.1) 13.3 (11.4–16.1) 11.0 (8.6–14.3)
Missing 10,973 723 1794 1219 2721 1471 3045
Random glucose, mmol/l
Mean (SD) 11.2 (4.4) 13.6 (5.7) 11.2 (5.6) 12.1 (4.7) 10.3 (3.6) 12.8 (4.0) 10.3 (4.0)
Median (IQR) 10.3 (8.0–13.3) 11.9 (9.6–16.7) 9.7 (7.5–12.8) 12.0 (8.4–15.0) 9.5 (7.9–11.8) 12.3 (10.0–15.2) 9.4 (7.4–12.3)
Missing 13,153 644 1795 2997 2940 1785 2992
BMI, kg/m2
Mean (SD) 29.1 (5.9) 30.6 (6.2) 30.6 (6.1) 27.3 (4.5) 31.9 (6.1) 31.1 (5.7) 26.1 (5.0)
Median (IQR) 28.1 (25.0–32.3) 29.7 (26.3–34.0) 29.6 (26.4–34.0) 26.8 (24.2–29.8) 31.1 (27.6–35.1) 30.4 (27.3–34.1) 25.4 (22.9–28.3)
Missing 1235 13 202 208 261 326 225
SBP, mmHg
Mean (SD) 132.3 (16.5) 134.2 (18.6) 131.2 (17.7) 128.8 (15.2) 136.4 (16.6) 133.3 (15.7) 131.6 (16.0)
Median (IQR) 130.0 (120.0–140.0) 130.0 (120.0–142.0) 130.0 (120.0–140.0) 130.0 (120.0–138.0) 135.0 (125.0–145.0) 130.0 (120.0–140.0) 130.0 (120.0–140.0)
<140 10,332 (67.7) 548 (67.7) 1323 (69.1) 2529 (76.1) 1805 (56.5) 1302 (64.1) 2825 (71.0)
Missing 740 3 86 38 282 151 180
d
ia
b
e
t
e
s
r
e
s
e
a
r
c
h
a
n
d
c
l
in
ic
a
l
p
r
a
c
t
ic
e
1
5
1
(2
0
1
9
)
2
0
–
3
2
2
7
metformin and a sulfonylurea. Prescription of combination
therapies as first-line treatment may reflect initiation of phar-
macological therapy in patients with high HbA1c levels; physi-
cians may have adopted a similar approach to the American
Association of Clinical Endocrinologists (AACE) and the Amer-
ican College of Endocrinology (ACE) treatment algorithm,
which recommends the use of metformin with a second
agent for newly diagnosed patients with an HbA1c level of
7.5% or more [8]. It should be noted, however, that combina-
tions of metformin and sulfonylureas come last in the hierar-
chy of first-line therapies suggested by the AACE/ACE for
patients with an HbA1c level of 7.5% or more. Alternatively,
physicians may prescribe lower doses of more than one med-
ication in order to address more than one physio-pathologic
aspect of the disease, and reduce the risk of adverse events.
The high prevalence of the use of combinations of metformin
and sulfonylureas is likely to be driven by the low cost of
these drugs rather than clinical evidence, particularly in
low- to middle-income countries. In addition, many countries
participating in DISCOVER have limited formularies, with
sodium–glucose-linked transporter type 2 inhibitors and
DPP-4 inhibitors being rarely available [26,27]. Slightly more
than 20% of patients received a first-line therapy that did
not include metformin.
Second-line therapies varied greatly across regions. The
most prescribed second-line therapies were combinations of
metformin and a sulfonylurea (Africa, South-East Asia and
the Western Pacific region), and combinations of metformin
and a DPP-4 inhibitor (Americas, Europe and the Eastern
Mediterranean region). Of note, approximately 13% of
patients received a single glucose-lowering agent as second-
line therapy, suggesting that many patients switched between
monotherapies. Although switching between monotherapies
may be appropriate for patients who did not tolerate their
first-line treatment, such switches are not in line with guide-
line recommendations for the majority of patients for whom
lack of efficacy was reported as a reason for treatment change
[6–11]. Insulin (on its own or as part of a combination) was
prescribed in 7.8% of patients, for whom the mean HbA1c level
was 9.9%. This high mean HbA1c level was similar to levels
reported in other observational studies of patients initiating
insulin [28,29] and is consistent with the recommendations
of clinical guidelines [6,8,10].
4.1. Strengths and limitations
The DISCOVER study programme includes nearly 16,000
patients, with global coverage including many countries that
have rarely or never been studied before regarding the man-
agement and outcomes of patients with type 2 diabetes mel-
litus. Previous international studies have usually focussed on
patients with more advanced disease; for example, A1chieve
and IMPROVE both studied patients receiving insulin therapy,
and the International Diabetes Management Practice Study
included patients with a mean diabetes duration of 8.4 years
[5]. DISCOVER therefore provides unique insights into treat-
ment practices at an earlier point in disease progression, at
a stage where guideline recommendations diversify. Long-
term follow-up will provide an opportunity to assess the asso-
ciations between treatment choices and clinical outcomes.
D
B
P,
m
m
H
g
M
e
a
n
(S
D
)
7
9
.9
(1
0
.0
)
8
0.
1
(1
0
.5
)
8
0.
6
(1
0
.6
)
7
9
.9
(8
.4
)
8
1.
1
(9
.6
)
7
9.
8
(9
.7
)
7
8.
6
(1
0
.9
)
M
e
d
ia
n
(I
Q
R
)
8
0
.0
(7
2
.0
–8
6
.0
)
8
0.
0
(7
1
.0
–8
7
.0
)
8
0.
0
(7
3
.0
–8
7
.0
)
8
0
.0
(7
4.
0
–8
5
.0
)
8
0.
0
(7
5
.0
–8
7
.0
)
8
0.
0
(7
3
.0
–8
5
.0
)
8
0.
0
(7
1
.0
–8
5
.0
)
M
is
si
n
g
7
5
3
3
8
6
4
1
2
82
1
54
1
87
H
y
p
e
rt
e
n
si
o
n
8
2
2
6
(5
1
.5
)
4
63
(5
7.
0
)
1
14
7
(5
7
.3
)
1
4
7
0
(4
3.
8
)
2
35
1
(6
8
.0
)
8
71
(3
9.
9
)
1
92
4
(4
6
.3
)
M
is
si
n
g
2
1
0
0
0
2
1
0
0
L
D
L-
C
,
m
g
/d
l
M
e
a
n
(S
D
)
1
0
9
.2
(3
8.
4
)
1
05
.2
(3
6
.4
)
1
02
.4
(4
0
.3
)
1
0
2
.5
(3
6
.2
)
1
12
.0
(4
2.
3
)
1
14
.3
(3
9
.1
)
1
10
.9
(3
4
.8
)
M
e
d
ia
n
(I
Q
R
)
1
0
5
.0
(8
3.
0
–1
3
2
.0
)
1
04
.2
(7
9
.0
–1
2
7
.0
)
9
7.
6
(7
3
.4
–1
2
7
.0
)
9
9
.0
(7
8.
4
–1
2
3
.0
)
1
06
.0
(8
2.
5
–1
3
7
.0
)
1
11
.0
(8
7
.0
–1
3
9
.0
)
1
09
.0
(8
8
.0
–1
3
2
.0
)
<
1
00
3
8
0
8
(4
3
.4
)
1
38
(4
4.
1
)
5
17
(5
3.
0
)
6
8
4
(5
0
.2
)
9
14
(4
3.
2
)
4
37
(3
8.
6
)
1
11
8
(3
9
.0
)
M
is
si
n
g
7
2
2
7
4
99
1
02
7
1
9
9
7
1
36
1
1
04
9
1
29
4
H
y
p
e
rl
ip
id
a
e
m
ia
7
2
8
4
(4
5
.6
)
3
24
(3
9.
9
)
9
79
(4
8.
9
)
1
1
7
6
(3
5.
0
)
1
91
8
(5
5
.5
)
9
10
(4
1.
7
)
1
97
7
(4
7
.6
)
M
is
si
n
g
2
1
0
0
0
2
1
0
0
M
ic
ro
v
a
sc
u
la
r
co
m
p
li
ca
ti
o
n
sa
3
0
1
1
(1
8
.9
)
1
18
(1
4.
5
)
3
02
(1
5.
1
)
5
5
6
(1
6
.5
)
8
12
(2
3.
5
)
3
99
(1
8.
3
)
8
24
(1
9.
8
)
M
is
si
n
g
2
1
0
0
0
2
1
0
0
M
a
cr
o
v
a
sc
u
la
r
co
m
p
li
ca
ti
o
n
sb
2
0
2
8
(1
2
.7
)
7
4
(9
.1
)
2
32
(1
1.
6
)
1
3
5
(4
.0
)
9
15
(2
6.
6
)
2
18
(1
0.
0
)
4
54
(1
0.
9
)
M
is
si
n
g
4
5
0
0
0
4
5
0
0
B
M
I,
b
o
d
y
m
a
ss
in
d
e
x
;D
B
P,
d
ia
st
o
li
c
b
lo
o
d
p
re
ss
u
re
;F
P
G
,f
a
st
in
g
p
la
sm
a
g
lu
co
se
;H
b
A
1
c
,g
ly
ca
te
d
h
a
e
m
o
g
lo
b
in
;I
Q
R
,i
n
te
rq
u
a
rt
il
e
ra
n
g
e
;L
D
L
-C
,l
o
w
-d
e
n
si
ty
li
p
o
p
ro
te
in
ch
o
le
st
e
ro
l;
P
P
G
,p
o
st
-p
ra
n
d
ia
l
g
lu
co
se
;
S
B
P,
sy
st
o
li
c
b
lo
o
d
p
re
ss
u
re
;
S
D
,
st
a
n
d
a
rd
d
ev
ia
ti
o
n
.
D
a
ta
a
re
re
p
o
rt
e
d
a
s
n
(%
),
u
n
le
ss
o
th
e
rw
is
e
st
a
te
d
.
P
e
rc
e
n
ta
g
e
s
ca
lc
u
la
te
d
fo
r
a
ll
p
a
ti
e
n
ts
w
it
h
d
a
ta
a
v
a
il
a
b
le
;
m
is
si
n
g
d
a
ta
a
re
e
x
cl
u
d
e
d
.
a
M
ic
ro
v
a
sc
u
la
r
co
m
p
li
ca
ti
o
n
s
in
cl
u
d
e
d
a
h
is
to
ry
o
f
ch
ro
n
ic
k
id
n
ey
d
is
e
a
se
,
re
ti
n
o
p
a
th
y,
re
ti
n
a
l
la
se
r
p
h
o
to
co
a
g
u
la
ti
o
n
,
a
u
to
n
o
m
ic
n
e
u
ro
p
a
th
y,
p
e
ri
p
h
e
ra
l
n
e
u
ro
p
a
th
y
a
n
d
e
re
ct
il
e
d
y
sf
u
n
ct
io
n
.
b
M
a
cr
o
v
a
sc
u
la
r
co
m
p
li
ca
ti
o
n
s
in
cl
u
d
e
d
a
h
is
to
ry
o
f
co
ro
n
a
ry
a
rt
e
ry
d
is
e
a
se
,h
e
a
rt
fa
il
u
re
,a
n
g
in
a
,m
y
o
ca
rd
ia
l
in
fa
rc
ti
o
n
,p
e
rc
u
ta
n
e
o
u
s
co
ro
n
a
ry
in
te
rv
e
n
ti
o
n
,c
o
ro
n
a
ry
a
rt
e
ry
b
y
p
a
ss
g
ra
ft
in
g
,s
tr
o
k
e
,
tr
a
n
si
e
n
t
is
ch
a
e
m
ic
a
tt
a
ck
,
ca
ro
ti
d
a
rt
e
ry
st
e
n
t,
ca
ro
ti
d
e
n
d
a
rt
e
re
ct
o
m
y,
p
e
ri
p
h
e
ra
l
a
rt
e
ry
d
is
e
a
se
,
d
ia
b
e
ti
c
fo
o
t,
a
m
p
u
ta
ti
o
n
a
n
d
im
p
la
n
ta
b
le
ca
rd
io
v
e
rt
e
r
d
e
fi
b
ri
ll
a
to
r
u
se
.
28 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 5 1 ( 2 0 1 9 ) 2 0 –3 2
Table 4 – First- and second-line therapies of patients participating in the DISCOVER study.
Total
(N = 15,992)
Africa
(n = 812)
Americas
(n = 2002)
South-East Asia
(n = 3360)
Europe
(n = 3479)
Eastern
Mediterranean
(n = 2182)
Western Pacific
(n = 4157)
First-line therapy
Metformin monotherapy 8882 (55.6) 679 (83.6) 1543 (77.1) 1505 (44.8) 2331 (67.1) 1057 (48.5) 1767 (42.5)
SU monotherapy 1229 (7.7) 27 (3.3) 137 (6.8) 186 (5.5) 268 (7.7) 288 (13.2) 323 (7.8)
DPP-4i monotherapy 1194 (7.5) 1 (0.1) 40 (2.0) 43 (1.3) 53 (1.5) 19 (0.9) 1038 (25.0)
Other monotherapya 630 (3.9) 2 (0.2) 18 (0.9) 33 (1.0) 61 (1.8) 13 (0.6) 503 (12.1)
Metformin + SU 2304 (14.4) 73 (9.0) 135 (6.7) 1045 (31.1) 287 (8.3) 522 (23.9) 242 (5.8)
Metformin + DPP-4i 501 (3.1) 1 (0.1) 94 (4.7) 123 (3.7) 95 (2.7) 131 (6.0) 57 (1.4)
Metformin + SU + DPP-4i 217 (1.4) 1 (0.1) 14 (0.7) 97 (2.9) 26 (0.7) 70 (3.2) 9 (0.2)
Metformin + other(s) 848 (5.3) 25 (3.1) 13 (0.6) 291 (8.7) 323 (9.3) 42 (1.9) 154 (3.7)
Other combinations 183 (1.1) 3 (0.4) 8 (0.4) 37 (1.1) 32 (0.9) 39 (1.8) 64 (1.5)
Missing 4 0 0 0 3 1 0
Second-line therapy
Metformin monotherapy 315 (2.0) 8 (1.0) 40 (2.0) 56 (1.7) 76 (2.2) 27 (1.2) 108 (2.6)
SU monotherapy 441 (2.8) 26 (3.2) 28 (1.4) 87 (2.6) 172 (4.9) 32 (1.5) 96 (2.3)
DPP-4i monotherapy 669 (4.2) 3 (0.4) 69 (3.4) 133 (4.0) 161 (4.6) 72 (3.3) 231 (5.6)
Other monotherapyb 625 (3.9) 3 (0.4) 43 (2.1) 256 (7.6) 107 (3.1) 37 (1.7) 179 (4.3)
Metformin + SU 3336 (20.9) 464 (57.1) 578 (28.9) 832 (24.8) 566 (16.3) 331 (15.2) 565 (13.6)
Metformin + DPP-4i 3756 (23.5) 18 (2.2) 584 (29.2) 522 (15.5) 956 (27.5) 645 (29.6) 1031 (24.8)
Metformin + SU + DPP-4i 1054 (6.6) 1 (0.1) 71 (3.5) 360 (10.7) 141 (4.1) 440 (20.2) 41 (1.0)
Metformin + other(s)c 3103 (19.4) 188 (23.2) 381 (19.0) 803 (23.9) 766 (22.0) 317 (14.5) 648 (15.6)
Other combinationsc 1449 (9.1) 14 (1.7) 62 (3.1) 153 (4.6) 179 (5.1) 129 (5.9) 912 (21.9)
Insulind 1240 (7.8) 87 (10.7) 146 (7.3) 158 (4.7) 352 (10.1) 151 (6.9) 346 (8.3)
Missing 4 0 0 0 3 1 0
DPP-4i, dipeptidyl peptidase-4 inhibitor; SU, sulfonylurea.
Data are reported as n (%). Percentages calculated for all patients with data available; missing data are excluded.
a Including a-glucosidase inhibitors, thiazolidinediones, meglitinides and sodium–glucose cotransporter-2 inhibitors.
b Including a-glucosidase inhibitors, thiazolidinediones, meglitinides, sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
c Excluding insulin.
d On its own or as part of combinations.
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The large population size of DISCOVER will provide the oppor-
tunity to analyse events with low incidences, and the use of a
standardized electronic case report form for data collection
allows the comparison of results within and across countries
and regions.
Although sites were carefully selected to be as representa-
tive as possible of themanagement of type 2 diabetes mellitus
in each participating country, as in any observational study of
this nature it was not possible to obtain a fully representative
sample (Supplementary Fig. 1). There are several reasons for
this including low numbers of sites in some countries, infras-
tructure challenges that prevented the inclusion of some sites
in rural locations, and the fact that some centres, often those
involved in primary care, did not have the capability of run-
ning observational research or failed to meet other quality
requirements. In some countries, little information was avail-
able to be collated before the start of the study.
Patient selection bias should also be considered; for exam-
ple, more than three-quarters of participants were reported to
have secondary or higher education, a greater proportion
than would be anticipated and potentially reflecting an
increased willingness among educated patients to take part
in the study. In addition, less than a third of patients reported
alcohol or tobacco use, which may indicate selective disclo-
sure or suppression of information. Together, these observa-
tions may also reflect a selection bias for patients of higher
socio-economic status, which should be considered when
interpreting the results from the DISCOVER study. Indeed,
these patients are likely to receive better care and therefore
to have better outcomes than the general population of
patients initiating a second-line glucose-lowering therapy.
Nevertheless, the patient population included in DIS-
COVER is large and heterogeneous, resulting in a unique
opportunity to assess associations between clinical
Patient request
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Fig. 1 – Reasons cited by investigators for (a) changing first-line therapy and (b) choosing a second-line therapy for patients
participating in the DISCOVER study. Multiple reasons could be selected.
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outcomes, treatment options and other factors in a global
context. Over-representation of urban locations, secondary
care and highly educated patients is likely to lead to an
over-estimate, rather than an underestimate, of the quality
of care in at least some countries. Another possibility is that
over-representation of secondary care may result in the inclu-
sion of patients withmore severe disease, who are more likely
to be referred to hospitals and for specialist management.
The observational design of DISCOVER also means that
data are collected in accordance with routine clinical practice
at each participating site. Data collection was not mandatory
for any variable, and the study protocol did not specify stan-
dardized methods to measure clinical variables such as
HbA1c. Methodology may therefore vary across sites and
countries. The results, however, are reflective of clinical prac-
tice. Finally, events such as occurrence of complications were
not adjudicated, and diagnosis relied on the judgement of
treating physicians.
4.2. Conclusions
Baseline data from the DISCOVER study highlight substantial
variations in healthcare systems, characteristics and treat-
ment of patients with type 2 diabetes mellitus between geo-
graphic regions. The great diversity of prescribed treatments
confirms that uncertainty remains regarding the optimal
choice of second-line therapy in clinical practice. Among this
population of patients initiating second-line therapy, HbA1c
levels and the prevalence of vascular complications and asso-
ciated risk factors were high, highlighting a global need for
more aggressive risk-factor management. The 3-year follow-
up of DISCOVER patients will allow the comparison of out-
comes associated with different therapies, thus providing
insights on the optimal use of available glucose-lowering
drugs.
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